

IMMUCELL CORP /DE/
Form 8-K
June 19, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: June 19, 2012
(Date of earliest event reported)

ImmuCell Corporation
(Exact name of registrant as specified in its charter)

ME
(State or other jurisdiction
of incorporation) 001-12934

(Commission File Number) 01-0382980
(IRS Employer

Identification Number)

56 Evergreen Drive
(Address of principal executive offices) 04103

(Zip Code)
207-878-2770
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On June 18, 2012 ImmuCell Corporation (the "Company") issued a press release announcing that it presented a strategic overview of the Company's business at its Annual Meeting of Stockholders on June 14, 2012 and has posted this information on the Investor Relations section of its web-site. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits

(a) Financial statements:

None

(b) Pro forma financial information:

None

(c) Shell company transactions:

None

(d) Exhibits

99.1 Press Release of ImmuCell Corporation dated June 19, 2012

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 19, 2012

IMMUCELL CORPORATION

By: /s/ Michael F. Brigham

Michael F. Brigham

President and CEO

Exhibit Index **Exhibit No.** **Description** 99.1 Press Release of ImmuCell Corporation dated June 19, 2012